



Reg. Office: 28, Level 1, am @ 10, MB Towers, H No. 8-2-624/A/1, Road No. 10, Banjara Hills, Hyderabad – 500034, Telangana
Corp Office: Office No. 201, Citi Mall, Link Road, Andheri West, Mumbai – 400053
Email ID: rubraltd@gmail.com | **Website:** www.rubramed.com
CIN: L33100TG1991PLC013266 | **Tel:** +91 9167469649

November 10, 2017

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code: 531099

Sub: Outcome of Board Meeting


Dear Sir(s),

The Board of Directors in their meeting held today i.e. November 10, 2017 has approved the Un-audited Financial Results of the Company for the Quarter and half year ended September 30, 2017.

You are requested to take note of the same.

Thanking you,

Yours faithfully,
For **Rubra Medicaments Limited**


Abha Kapoor
Director (Finance) and Chief Financial Officer
DIN – 02799429

RUBRA MEDICAMENTS LIMITED

Statement of Standalone Unaudited Financial Results for the quarter and Half year ended September 30, 2017

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceding 3 months ended	Figures for corresponding 3 months ended in the previous year	Year to date Figures for current period ended	Year to date Figures for previous period ended	Figures for the previous year ended
		30-Sep-2017	30-Jun-2017	30-Sep-2016	30-Sep-2017	30-Sep-2016	31-Mar-2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	103.42	92.30	7.88	195.72	15.13	30.62
II	Other Income	9.28	6.70	0.00	15.98	0.00	0.25
III	Total Income (I + II)	112.70	99.00	7.88	211.70	15.13	30.87
IV	Expenses:						
	Cost of Materials Consumed	0	0.00	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	101.53	86.94	4.36	188.47	7.93	12.13
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	3.08	0.32	0.45	3.40	0.90	2.00
	Finance Costs	0.00	0.00	0.00	0.00	0.00	0.01
	Depreciation & amortisation expense	0.01	0.01	0.01	0.02	0.01	0.03
	Other Expenses	5.05	6.66	2.03	11.71	4.79	13.31
	Total Expenses (IV)	109.67	93.93	6.85	203.60	13.63	27.48
V	Profit / (loss) before exceptional items and tax (III-IV)	3.03	5.07	1.03	8.10	1.50	3.39
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit / (loss) before tax (V-VI)	3.03	5.07	1.03	8.10	1.50	3.39
VIII	Tax Expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	3.03	5.07	1.03	8.10	1.50	3.39
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinuing operations (after tax)(X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX+XII)	3.03	5.07	1.03	8.10	1.50	3.39
XIV	Other comprehensive income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	3.03	5.07	1.03	8.10	1.50	3.39
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic	0.06	0.09	0.02	0.15	0.03	0.06
	(2) Diluted	0.06	0.09	0.02	0.15	0.03	0.06
XVII	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	Earnings per equity share (for discontinued & continuing operation):						
	(1) Basic	0.06	0.09	0.02	0.15	0.03	0.06
	(2) Diluted	0.06	0.09	0.02	0.15	0.03	0.06
1	NOTES:						
2	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.						
3	The Segment - wise details are not applicable to the Company as the Company has no segments.						
4	The results are Ind-AS compliant however, the previous year figures are not subject to limit review or audit. However the management has exercised necessary due - diligence to ensure that the Financial Results provide a true and fair view of its affairs.						
5	The result is provisional and unaudited and subject to change, regrouping and restatement.						

For Rubra Medicaments Limited

Place: Mumbai
Date:- November 10, 2017


Abha Kapoor
 Director (Finance) & CFO
 DIN: 02799429

RUBRA MEDICAMENTS LIMITED

(Rs. in Lakhs)

STATEMENT OF ASSETS AND LIABILITIES

	Particulars	Figures as at the end of current reporting period	Figures as at the end of the previous reporting period
		September 30, 2017	March 31, 2017
		Unaudited	Audited
	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	0.06	0.08
	(b) Capital work-in-progress	-	-
	(c) Investment property	-	-
	(d) Goodwill	-	-
	(e) Other intangible assets	-	-
	(f) Intangible assets under development	-	-
	(g) Biological assets other than bearer plants	-	-
	(h) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Loans	-	-
	(iv) Others (to be specified) - Advances	38.89	33.79
	(i) Deferred tax assets (net)	-	-
	(j) Other non-current assets	1.69	1.69
	Total non-current assets	40.64	35.56
2	Current assets		
	(a) Inventories	2.37	-
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	1.77	1.77
	(iii) Cash and cash equivalents	25.09	15.55
	(iv) Bank balances other than (iii) above	-	-
	(v) Loans	-	-
	(vi) Others to be specified - Advances	-	-
	(c) Current tax assets (net)	-	-
	(d) Other current assets	-	-
	Total current assets	29.23	17.32
	Total assets	69.87	52.88
1	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital	546.83	546.83
	(b) Other equity	-496.93	-505.03
	Total equity	49.90	41.80
	LIABILITIES		
2	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (net)	7.47	7.47
	(d) Other non-current liabilities	-	-
	Total non-current liabilities	7.47	7.47
	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	10.00	-
	(ii) Trade payables	2.32	3.32
	(iii) Other financial liabilities (other than those specified in item (a))	-	-
	(b) Other current liabilities	-	-
	(c) Provisions, current	0.18	0.29
	(d) Current tax liabilities (Net)	-	-
	Total current liabilities	12.50	3.61
	Total liabilities	19.97	11.08
	Total Equity and Liabilities	69.87	52.88

Limited Review Report of the Auditors

To,
The Board of Directors
Rubra Medicaments Limited
Hyderabad

Sub: Limited Review Report

We have reviewed the accompanying statement of unaudited financial results of Rubra Medicaments Limited for the period ended September 30, 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Prakash Modi & Associates
Chartered Accountant
FRN: 116900W

Prakash Modi

Prakash Modi
Partner
M. No. 101463



Place: Mumbai

Date: 10th November, 2017